20270 - Ph2 MRTX849 Pembro NSCLC KRAS

A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Disease Types: Lung (Non Small Cell),&nbs

Available at: {clinical_trial_location backspace="7"}20270 - Ph2 MRTX849 Pembro NSCLC KRAS, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}